- Home
- / Effector Therapeutics
Effector Therapeutics
Stock Price
$0
2024-10-29
Market Capitalization
$1.9 K
2024-10-29
Revenue
$3.6 M
FY, 2022
Effector Therapeutics Summary
Company Summary
- Overview
- Effector Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer and other serious diseases.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- Solana Beach, CA, US | view all locations
- Website
- http://effector.com
- Cybersecurity rating
Table of Contents
Key People
Steve Worland, President, Chief Executive Officer and Director
Mark Densel, Vice President, Development Operations
Mike Byrnes, Chief Financial Officer
LocationsView all
2 locations detected
Solana Beach, CA HQ
United States
142 N Cedros Ave # B
San Diego, CA
United States
11120 Roselle St a
Effector Therapeutics Financials
Summary Financials
- Net income (Q1, 2024)
- ($8.8M)
- Cash (Q1, 2024)
- $15.5M
- EBIT (Q1, 2024)
- ($8.4M)
- Enterprise value
- $4.0M